Cellectis (CLLS) Says FDA Grants IND Approval to Proceed with Clinical Development of UCART123 – StreetInsider.com
|
Cellectis (CLLS) Says FDA Grants IND Approval to Proceed with Clinical Development of UCART123
StreetInsider.com Cellectis (NASDAQ: CLLS), a biopharmaceutical company focused on developing immunotherapies based on gene edited CAR T-cells (UCART), has received an Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA) to … Cellectis gets green light to start clinical trials in US with UCART123; shares ahead 9% after hours Cellectis gets US go-ahead to test ‘off-the-shelf’ cell therapy |
View original article
Author:
Powered by WPeMatico
Health Topic Contributor
Editors and curators bringing you the latest and most impactful health news. Truly objective, we print links to stories and studies that may contradict one another. If you're searching for news on health studies, alternative health modalities, facts on modern allopathic medicine, and more, we're you're team bringing you the stories and facts that matter.